RG
PBYI icon

Redmile Group’s Puma Biotechnology PBYI Stock Holding History

Redmile Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,095,612
Closed -$74.6M – 83
2018
Q1 		$74.6M Buy
1,095,612
+182,039
+20% +$13.6M 2.88% 9
2017
Q4 		$90.3M Buy
913,573
+6,931
+0.8% +$776K 3.93% 3
2017
Q3 		$109M Buy
906,642
+46,186
+5% +$4.3M 5.36% 3
2017
Q2 		$75.2M Sell
860,456
-864,958
-50% -$48.4M 4.58% 4
2017
Q1 		$64.2M Buy
1,725,414
+435,274
+34% +$15.9M 4.17% 4
2016
Q4 		$39.6M Buy
1,290,140
+627,854
+95% +$27.1M 3.41% 10
2016
Q3 		$44.4M Buy
+662,286
New +$33.5M 3.53% 10
2015
Q1 		– Sell
-93,865
Closed -$17.8M – 63
2014
Q4 		$17.8M Buy
93,865
+42,840
+84% +$9.5M 1.93% 18
2014
Q3 		$12.2M Buy
+51,025
New +$10.5M 1.41% 32
2014
Q2 		– Sell
-172,092
Closed -$17.9M – 55
2014
Q1 		$17.9M Sell
172,092
-58,581
-25% -$6.89M 2.14% 21
2013
Q4 		$23.9M Sell
230,673
-109,492
-32% -$6.43M 2.95% 7
2013
Q3 		$18.3M Sell
340,165
-199,829
-37% -$10.8M 2.75% 14
2013
Q2 		$24M Buy
+539,994
New +$19M 4.22% 6

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Redmile Group's PBYI Position: Q2 2018 in Review

Redmile Group sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 1,095,612 shares — an estimated $74.6M sold.

Redmile Group first reported a position in PBYI in Q2 2013 and held it in 13 quarters. The position peaked at $109M in Q3 2017. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

  • Redmile Group reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Redmile Group sold 1,095,612 Puma Biotechnology shares in Q2 2018, an estimated $74.6M.
  • Redmile Group first reported a position in Puma Biotechnology in Q2 2013 and held it in 13 quarters.
  • Redmile Group's Puma Biotechnology position peaked at $109M in Q3 2017.
  • 174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.